Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia
Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
The investigators propose to test whether curcumin nanoparticles will improve behavioral
measures and biomarkers of cognition and neuroplasticity in patients with schizophrenia who
are already receiving a stable dose of antipsychotic.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
VA Greater Los Angeles Healthcare System
Collaborators:
Stanley Medical Research Institute Theravalues, Inc. University of California, Los Angeles